TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07179692: Clinical Study of CEA-Targeted Chimeric Antigen Receptor T Lymphocytes (CAR-T) in Advanced CEA-Positive Malignant Solid Tumors

Sponsor: Chongqing Precision Biotech Co., Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 108 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07179692 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07179692 Rescue Dossier →